불가리아 - 불가리아어 - БАБХ (Българска агенция по безопасност на храните)

ЕТ ЯНЧО ТОДОРОВ - toldimfos тригидрат натрий - инжекционен разтвор - 200 mg/ml - говеда

불가리아 - 불가리아어 - БАБХ (Българска агенция по безопасност на храните)

„АСКЛЕП - ФАРМА” ООД - Амоксицилин (като амоксициллина тригидрат); clavulonic киселина (под формата на клавуланата калий) - таблетки - 40 mg, 200 mg/таблетка; 10 mg,50 mg/таблетка - кучета

불가리아 - 불가리아어 - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v - Фенбендазола - премикс за медикаментозен фураж; перорален прах - 40 mg/g - прасета

불가리아 - 불가리아어 - БАБХ (Българска агенция по безопасност на храните)

warburton technology - zinc, manganese, copper, selenium - инжекционен разтвор - 60 mg, 10 mg, 15 mg, 5 mg/ml - говеда

불가리아 - 불가리아어 - Ecolab

ecolab deutschland gmbh -

불가리아 - 불가리아어 - Ecolab

ecolab deutschland gmbh -

불가리아 - 불가리아어 - Ecolab

ecolab deutschland gmbh -

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - етапенем натрий - Бактериални инфекции - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 и 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. Трябва да се вземат предвид официалните препоръки за правилното използване на антибактериални агенти.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - терипаратид - osteoporosis; osteoporosis, postmenopausal - Калциева хомеостаза - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.